✦ LIBER ✦

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

✍ Scribed by Inna V. Fedorenko; Kim H.T. Paraiso; Keiran S.M. Smalley

Book ID: 118426425
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 582 KB
Volume: 82
Category: Article
ISSN: 0006-2952
DOI: 10.1016/j.bcp.2011.05.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

BRAF and MEK inhibitors in BRAF-mutant m

BRAF and MEK inhibitors in BRAF-mutant melanoma

✍ Sharan Prakash Sharma 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 126 KB

BRAF inhibitor activity in V600R metasta

BRAF inhibitor activity in V600R metastatic melanoma

✍ Klein, Oliver; Clements, Arthur; Menzies, Alexander M.; O’Toole, Sandra; Kefford 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 793 KB

BRAF Gene Amplification Can Promote Acqu

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

✍ Corcoran, R. B.; Dias-Santagata, D.; Bergethon, K.; Iafrate, A. J.; Settleman, J 📂 Article 📅 2010 🏛 American Association for the Advancement of Scienc 🌐 English ⚖ 745 KB

BRAF inhibitor activity in V600R metasta

BRAF inhibitor activity in V600R metastatic melanoma – Response

✍ Klein, Oliver; Clements, Arthur; Menzies, Alexander M.; O’Toole, Sandra; Kefford 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 284 KB

Combined BRAF and MEK Inhibition in Mela

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

✍ Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Ri 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 528 KB

Combined BRAF and MEK Inhibition in Mela

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

✍ Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Ri 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 528 KB

## Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with da braf e nib, a selective BRAF inhibitor, and trametinib, a